Development of a HER1/CP2c dual-targeting biopharmaceutical for HER1-overexpressing head and neck cancer - PubMed
a day ago
- #head and neck cancer
- #HER1 targeting
- #biopharmaceutical
- Development of a HER1/CP2c dual-targeting biopharmaceutical named DTAT-D351 (Cetuximab scFv-CPTin) for HER1-overexpressing head and neck cancer.
- DTAT-D351 combines a HER1-targeting scFv with a cytotoxic payload targeting oncoprotein CP2c, linked by a cleavable sequence activated by MMP-11.
- The biopharmaceutical shows high productivity, strong HER1 binding affinity, and potent anticancer effects against HER1-overexpressing and A431 epidermoid carcinoma cells.
- DTAT-D351 demonstrates no adverse effects on immune cells and normal cells, indicating a favorable safety profile.
- The study presents DTAT-D351 as a promising therapeutic option for head and neck squamous cell carcinoma (HNSCC) and other HER1-overexpressing cancers.